Drugs / Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05345522 | Apr → Nov 2022 overdue | idiopathic multicentric Castleman disease | Beijing VDJBio Co., LTD. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05345522 ↗ |
| Known as | Anti-IL-6R mAb | “recombinant humanized anti-interleukin-6 receptor monoclonal antibody ( Anti-IL-6R mAb ) injection” NCT05345522 ↗ |
| Modality | Monoclonal antibody | “recombinant humanized anti-interleukin-6 receptor monoclonal antibody” NCT05345522 ↗ |
| Route | Intravenous | “intravenous injection” NCT05345522 ↗ |